Current Treatment Options in Aggressive Lymphoma

References

• Edwards, BK., Howe, H.L., Ries, L.A., Thun, M.J., Rosenberg, H.M., Yancik, R., et al. (2002) "Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden", Cancer, 94, 2766–2792.
   PubMed Web of Science ®Google Scholar
• Ries, L.A., Eisner, M.P., Kosary, CL., Hankey, B.F., Miller, BA., Clegg, L., etal. (2003) SEER Cancer Statistics Review, 1975–2000. Bethesda, MD: National Cancer Institute.
   Google Scholar
• Cohen, B.J., Moskowitz, C., Straus, D., Noy, A., Hedrick, E. and Zelenetz, A. (2001) "Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma", Leuk. Lymphoma, 42, 1015 — 1022.
   PubMed Web of Science ®Google Scholar
• Shipp, MA., Harrington, D.P., Armitage, J.P., Bonadonna, G., Canellos, G.P., Coiffier, B., et al. (1993) "A predictive model for aggressive non-Hodgkin's lymphoma", N. Engl. J. Med., 329, 987–994.
   Google Scholar
• Alizadeh, A., Eisen, M., Davis, RE., Ma, C., Sabet, H., Tran, T., et al. (1999) "The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes", Cold Spring Harb. Symp. Quant. Biol., 64, 71 — 78.
   PubMedGoogle Scholar
• Alizadeh, A.A., Eisen, MB., Davis, RE., Ma, C., Lossos, IS., Rosenwald, A., et al. (2000) "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling", Nature, 403, 503— 511.
   Google Scholar
• Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, RI., et al. (2002) "The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma", N. Engl. J. Med., 346, 1937— 1947.
   Web of Science ®Google Scholar
• McKelvey, EM., Gottlieb, J.A., Wilson, HE., Haut, A., Talley, R.W., Stephens, R., et al., (1976) "Hydroxyldaunomycin (Adria-mycin) combination chemotherapy in malignant lymphoma", Cancer, 38, 1484–1493.
   PubMed Web of Science ®Google Scholar
• Coiffier, B. (1995) "Fourteen years of high-dose CHOP (ACVB regimen): preliminary conclusions about the treatment of aggres-sive-lymphoma patients. Hamilton Fairley Award Lecture, Eur-opean Society for Medical Oncology Meeting, Lisbon, November 21, 1994", Ann. Oncol., 6,211–217.
   Google Scholar
• Miller, T.P., Dahlberg, S., Cassady, J.R., Adelstein, DJ., Spier, CM., Grogan, TM., etal. (1998) "Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma", N. Engl. J. Med., 339, 21— 26.
   Google Scholar
• Sonneveld, P., de Ridder, M., van der Lelie, H., Nieuwenhuis, K., Schouten, H., Mulder, A., et al. (1995) "Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy", J. Clin. °ilea, 13, 2530–2539.
   PubMed Web of Science ®Google Scholar
• Osby, E., Hagberg, H., Kvaloy, S., Teerenhovi, L., Anderson, H., Cavallin-Stahl, E., et al. (2003) "CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial", Blood, 101, 3840— 3848.
   Google Scholar
• De Lena, M., Maiello, E., Lorusso, V., Brandi, M., Calabrese, P., Romito, S., et al. (1989) "Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-Hodgkin's lymphomas. A randomized trial", Med. Oncol. Tumor Pharmacother., 6, 163–169.
   PubMedGoogle Scholar
• Kaplan, L.D., Straus, DJ., Testa, M.A., Von Roenn, J., Dezube, B.J., Cooley, T.P., et al. (1997) "Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lym-phoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group", N. Engl. J. Med., 336, 1641 —1648.
   Web of Science ®Google Scholar
• Longo, D.L., DeVita, V.T.J., Duffey, P.L., Wesley, M.N., Ihde, D.C., Hubbard, S.M., et al. (1991) "Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial [published erratum appears in J. Clin. Oncol. 1991 Apr;9(4):710]", J. Clin. Oncol., 9, 25–38.
   Web of Science ®Google Scholar
• Marotta, G., Bigazzi, C., Bocchia, M., Forconi, F. and Lauria, F. (1998) "Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype", Haematologica, 83, 853— 854.
   Google Scholar
• Resegotti, L., Vitolo, U., Bertini, M., Brusamolino, E., Comotti, B., Tarella, C., et al. (1991) "MACOP-B for advanced stage large cell lymphoma (DLCL). More is better? Italian Multiregional Cooperative Study Group (IMCSGL)", Leukemia, 5(Suppl 1), 86–89.
   PubMed Web of Science ®Google Scholar
• Khaled, H.M., Zekri, Z.K., Mokhtar, N., Ali, N.M., Darwish, T., Elattar, I., et al. (1999) "A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results", Ann. Oncol., 10, 1489 — 1492.
   Google Scholar
• Jerkeman, M., Anderson, H., Cavallin-Stahl, E., Dictor, M., Hagberg, H., Johnson, A., et al. (1999) "CHOP versus MACOP-B in aggressive lymphoma—a Nordic Lymphoma Group rando-mised trial", Ann. Oncol., 10, 1079–1086.
   PubMed Web of Science ®Google Scholar
• Montserrat, E., Garcia-Conde, J., Vinolas, N., Lopez-Guillermo, A., Hernandez-Nieto, L., Zubizarreta, A., et al. (1996) "CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodg-kin's lymphomas: long-term results of a multicenter randomized trial. (PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology)", Eur. J. Haematol., 57, 377 — 383.
   Google Scholar
• Cooper, IA., Wolf, M.M., Robertson, TI., Fox, R.M., Matthews, J.P., Stone, J.M., et al. (1994) "Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lym-phoma Group", J. Clin. Oncol., 12, 769–778.
   Web of Science ®Google Scholar
• Gordon, L.I., Harrington, D., Andersen, J., Colgan, J., Glick, J., Neiman, R., et al. (1992) "Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma", N. Engl. J. Med., 327, 1342— 1349.
   Google Scholar
• Wolf, M., Matthews, J.P., Stone, J., Cooper, IA., Robertson, T.I. and Fox, R.M. (1997) "Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group", Ann. Oncol., 8(Suppl 1), 71–75.
   Google Scholar
• Fisher, RI., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., et al. (1993) "Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma", N. Engl. J. Med,. 328, 1002 — 1006.
   Google Scholar
• Messori, A., Vaiani, M., Trippoli, S., Rigacci, L., Jerkeman, M. and Longo, G. (2001) "Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of rando-mized studies comparing third generation regimens with CHOP", Br. J. Cancer, 84, 303–307.
   Web of Science ®Google Scholar
• Schriber, J. (2002) "Treatment of aggressive non-Hodgkin's lymphoma with chemotherapy in combination with filgrastim", Drugs, 62\(Suppl 1), 33–46.
   PubMed Web of Science ®Google Scholar
• Itoh, K., Ohtsu, T., Fukuda, H., Sasaki, Y., Ogura, M., Morishima, Y., et al. (2002) "Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505", Ann. Oncol., 13, 1347 — 1355.
   Google Scholar
• Yamazaki, T., Sawada, U., Kura, Y., Ito, T., Kaneita, Y., Yasukawa, K., et al. (2002) "Dose-intensified CHOP (double-CHOP) followed by consolidation with high-dose chemotherapy for high and high-intermediate risk aggressive non-Hodgkin's lymphomas", Leuk. Lymphoma, 43, 2117 — 2123.
   PubMed Web of Science ®Google Scholar
• Wunderlich, A., Kloess, M., Reiser, M., Rudolph, C., Truemper, L., Bittner, S., et al. (2003) "Practicability and acute haema-tological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)", Ann. Oncol., 14, 881 — 893.
   Google Scholar
• Hotta, T., Shimakura, Y., Ishizuka, N., Fukuda, K., Itoh, K., Morishima, Y., et al. (2003) "Randomized phase III study of standard CHOP (s-CHOP) versus biweekly CHOP (Bi-CHOP) in aggressive non-Hodgkin's Lymphoma (NHL): Japan Clinical Oncology Group Study, JC0G9809", Proc. Am. Soc. Clin. Oncol., 22, 565 (Abstract 2271).
   Google Scholar
• Pfreundschuh, M., Truemper, L., Kloess, M., Schmits, R., Schmitz, N., Glass, B., et al. (2002) "2-weekly vs. 3-weekly CHOP with and without etoposide for patients 60 years of age with aggressive non-Hodgkin's lymphoma (NHL): Results of the completed NHL-B-2 trial of the DSHNHL", Blood, 100, 774a (Abstract 3060).
   Google Scholar
• Pfreundschuh, M., Truemper, L., Schmits, R., Kloess, M., Schmitz, N., Glass, B., et al. (2002) "2-weekly vs. 3-weekly CHOP with and without etoposide in young patients with low-risk (low LDH) aggressive non-Hodgkin's lymphoma: Results of the completed NHL-B-1 Trial of the DSHNHL", Blood, 100, 92a (Abstract 340).
   Google Scholar
• Verdonck, L.F., van Putten, W.L., Hagenbeek, A., Schouten, H.C., Sonneveld, P., van Imhoff, G.W., et al. (1995) "Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma", N. Engl. J. Med., 332, 1045— 1051.
   Google Scholar
• Wheeler, C., Strawderman, M., Ayash, L., Churchill, W.H., Bierer, B.E., Elias, A., et al. (1993) "Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmus-tine, and etoposide", J. Clin. Oncol., 11, 1085 — 1091.
   Web of Science ®Google Scholar
• Haioun, C., Lepage, E., Gisselbrecht, C., Coiffier, B., Bosly, A., Tilly, H., et al. (1994) "Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lym-phomes de l'Adulte", J. Clin. Oncol., 12, 2543–2551.
   Web of Science ®Google Scholar
• Vitolo, U., Cortellazzo, S., Liberati, A.M., Freilone, R., Falda, M., Bertini, M., et al. (1997) "Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma", J. Clin. Oncol., 15, 491–498.
   Web of Science ®Google Scholar
• Cortelazzo, S., Rossi, A., Viero, P., Bellavita, P., Marchioli, R., Marfisi, R.M., etal. (1997) "BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma", Br. J. Haematol., 99, 379 — 385.
   Google Scholar
• Gianni, A.M., Bregni, M., Siena, S., Brambilla, C., Di Nicola, M., Lombardi, F., et al. (1997) "High-dose chemotherapy and autologous bone marrow transplantation compared with MA-COP-B in aggressive B-cell lymphoma", N. Engl. J. Med., 336, 1290— 1297.
   Google Scholar
• Philip, T., Chauvin, F., Armitage, J., Bron, D., Hagenbeek, A., Biron, P., et al. (1991) "Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation", Blood, 77, 1587— 1592.
   Google Scholar
• Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., et al. (1995) "Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma", N. Engl. J. Med., 333, 1540 — 1545.
   Google Scholar
• Blay, J., Gomez, F., Sebban, C., Bachelot, T., Biron, P., Guglielmi, C., et al. (1998) "The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group", Blood, 92, 3562— 3568.
   Google Scholar
• Wilson, W.H., Gutierrez, M., O'Connor, P., Frankel, S., Jaffe, E., Chabner, B.A., et al. (2002) "The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R", Semin. Oncol., 29, 41–47.
   PubMed Web of Science ®Google Scholar
• Labar, B., Bogdanic, V., Nemet, D., Mrsic, M., Serventi-Seiwerth, R., Sertic, D., et al. (2002) "Allogeneic stem cell transplantation in treatment of aggressive lymphomas: case series", Croat. Med. J., 43, 565–568.
   PubMed Web of Science ®Google Scholar
• Dhedin, N., Giraudier, S., Gaulard, P., Esperou, H., Ifrah, N., Michallet, M., et al. (1999) "Allogeneic bone marrow transplanta-tion in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle", Br. J. Haematol., 107, 154— 161.
   Google Scholar
• Toze, C.L. and Barnett, M.J. (2002) "Allogeneic haemopoietic stem cell transplantation for non-Hodgkin's lymphoma", Best Pract. Res. Clin. Haematot, 15, 481–504.
   PubMed Web of Science ®Google Scholar
• Smith, S.M., Grinblatt, D. and van Besien, K. (2002) "Autologous and allogeneic transplantation for aggressive NHL", Cytotherapy, 4, 223–240.
   Google Scholar
• Schimmer, A.D., Jamal, S., Messner, H., Keating, A., Meharc-hand, J., Huebsch, L., etal. (2000) "Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada", Bone Marrow Transplant, 26, 859–864.
   PubMed Web of Science ®Google Scholar
• Moreau, P., Mechinaud, F., Mahe, B., Le Tortorec, S., Rapp, Mi., Maisonneuve, H., et al. (1996) "Successful allogeneic bone marrow transplantation for early relapse after autologous bone marrow transplantation in two cases of aggressive high-grade non-Hodgkin's lymphoma", Bone Marrow Transplant, 18, 665 —667.
   Google Scholar
• Martinez, C., Carreras, E., Rovira, M., Urbano-Ispizua, A., Esteve, J., Perales, M., et al. (2000) "Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation", Bone Marrow Transplant, 26, 677–679.
   PubMed Web of Science ®Google Scholar
• Grigg, A., Bardy, P., Byron, K., Seymour, J.F. and Szer, J. (1999) "Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma", Bone Marrow Transplant, 23, 107–110.
   Google Scholar
• Bertz, H., Illerhaus, G., Veelken, H. and Finke, J. (2002) "Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-in-tensity regimens", Ann. Oncol., 13, 135–139.
   Google Scholar
• Robinson, S.P., Goldstone, A.H., Mackinnon, S., Carella, A., Russell, N., de Elvira, CR., et al. (2002) "Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation", Blood, 100, 4310–4316.
   Google Scholar
• Coiffier, B. (2002) "Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodg-kin's lymphoma", Semin. Oncol., 29, 18 — 22.
   Google Scholar
• Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., et al. (2002) "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", N. Engl. J. Med., 346, 235–242.
   Google Scholar
• Vose, J., Link, BK., Grossbard, ML., Czuczman, MS., Grillo-Lopez, A.J., Benyunes, M., et al. (2002) "Long term follow-up of a phase II study of rituximab in combination with CHOP chemother-apy in patients with previously untreated aggressive non-Hodgkin's lymphoma (NHL)", Blood, 100, 361a (Abstract 1396).
   Google Scholar
• Ansell, S.M., Ristow, KM., Habermann, TM., Wiseman, GA. and Witzig, T.E. (2002) "Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritu-momab tiuxetan for non-Hodgkin's lymphoma", J. Clin. Oncol., 20, 3885–3890.
   Web of Science ®Google Scholar
• Leonard, J., Coleman, M., Kostakoglu, L., Morris, A.M., Gregory, S., Link, B., et al. (2001) "Bexxar (iodine tositumomab and tositumomab) can be administered safely in sequential combination with chemotherapy in initial treatment of non-Hodgkin's lymphoma (NHL)", Proc. Am. Soc. Clin. Oncol., 20, 287a 1–131 (Abstract 1146).
   Google Scholar
• Press, 0.W., Eary, J.F., Gooley, T., Gopal, A.J., Liu, S., Rajendran, J.G., et al. (2000) "A phaseI/II trial of iodine-131- tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lympho-ma", Blood, 96, 2934–2942.
   PubMed Web of Science ®Google Scholar
• Vose, J., Bierman, P.J., Lynch, J.C., Gobar, L., Augustine, S., Dukat, V., et al. (2001) "Radioimmunotherapy with Bexxar combined with high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell transplantation (ASCT) for refractory non-Hodgkin's lymphoma (NHL): synergistic results with no added toxicity", Proc. Am. Soc. Clin. Oncol., 20, 6a (Abstract 19).
   Google Scholar
• Raubitscheck, A., Nademanee, A., Molina, A., Rodriguez, R., White, CA. and Forman, S. (2000) "High dose radiotherapy/ chemotherapy and autologous stem cell transplantation (ASCT) for poor risk and relapsed CD20 + non-Hodgkin's lymphoma (NHL): early feasibility report", Blood, 96, 374b (Abstract 5372).
   Google Scholar
• Nademanee, A., Molina, A., Forman, S., Kogut, N., Yamauchi, D., Liu, A., et al. (2002) "A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL)", Blood, 100, 182a (Abstract 679).
   Google Scholar
• Winter, J., Inwards, D., Erwin, W., Wiseman, G., Rademaker, A., Patton, D., et al. (2001) "Phase I trial combining 90Y Zevalin and high dose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-cell non-Hodgkin's lympho-ma", Blood, 98, 677a (Abstract 2835).
   Google Scholar
• Winter, J.N., Inwards, D., Erwin, W., Wiseman, G., Rademaker, A., Patton, DR., et al. (2002) "Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma: early outcome results", Blood, 100, 411a (Abstract 1597).
   Google Scholar
• Rudiger, T., Weisenburger, D.D., Anderson, J.R., Armitage, J.0., Diebold, J., MacLennan, K.A., et al. (2002) "Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project", Ann. Oncol., 13, 140–149.
   PubMed Web of Science ®Google Scholar
• Waldmann, TA., White, JD., Carrasquillo, JA., Reynolds, J.C., Paik, C.H., Gansow, 0.A., et al. (1995) "Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yt-trium-90-labeled anti-Tac", Blood, 86, 4063–4075.
   PubMed Web of Science ®Google Scholar
• Kreitman, R.J., Wilson, W.H., White, JD., Stetler-Stevenson, M., Jaffe, E.S., Giardina, S., et al. (2000) "Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hema-tologic malignancies", J. Clin. Oncol., 18, 1622–1636.
   PubMed Web of Science ®Google Scholar
• Mercieca, J., Matutes, E., Dearden, C., MacLennan, K. and Catovsky, D. (1994) "The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype", J. Clin. Oncol., 12, 2588 — 2593.
   Web of Science ®Google Scholar
• Ho, A.D., Suciu, S., Stryckmans, P., De Cataldo, F., Willemze, R., Thaler, J., et al. (1999) "Pentostatin in T-cell malignancies — a phase II trial of the EORTC. Leukemia Cooperative Group", Ann. Oncol., 10, 1493–1498.
   Google Scholar
• Foss, F.M., Ihde, D.C., Linnoila, I.R., Fischmann, A.B., Schechter, G.P., Cotelingam, J.D., et al. (1994) "Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome", J. Clin. Oncol., 12, 2051–2059.
   Web of Science ®Google Scholar
• Scarisbrick, ii., Child, F.J., Clift, A., Sabroe, R., Whittaker, Si., Spittle, M., et al. (2001) "A trial of fludarabine and cyclopho-sphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma", Br. J. Dermatol., 144, 1010 — 1015.
   Web of Science ®Google Scholar
• Dearden, C.E., Matutes, E. and Catovsky, D. (2002) "Alemtuzu-mab in T-cell malignancies", Med. Oncol., 19(Suppl), S27 — 32.
   Google Scholar
• Hagberg, H., Lundin, J., Repp, R., Eriksson, M., Juliusson, G., Norberg, B., et al. (2001) "Phase II study of alemtuzumab (Campath-1H) in patients with advanced Mycosis Fungoides/ Sezary Syndrome", Blood, 98, 806a (Abstract 3352).
   Google Scholar
• Lain, T., Talpur, R. and Duvic, M. (2003) "Long-term control of mycosis fungoides of the hands with topical bexarotene", Int. J. Dermatol., 42, 238 — 241.
   Web of Science ®Google Scholar
• Talpur, R., Ward, S., Apisarnthanarax, N., Breuer-Mcham, J. and Duvic, M. (2002) "Optimizing bexarotene therapy for cutaneous T-cell lymphoma", J. Am. Acad. Dermatol., 47, 672–684.
   PubMed Web of Science ®Google Scholar
• Talpur, R., Apisarnthanarax, N., Ward, S. and Duvic, M. (2002) "Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK)", Leuk. Lymphoma, 43, 121 — 126.
   PubMed Web of Science ®Google Scholar
• Gorgun, G. and Foss, F. (2002) "Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox", Blood, 100, 1399 — 1403.
   Google Scholar
• Zaja, F., Russo, D., Silvestri, F., Fanin, R., Damiani, D., Infanti, L., et al. (1997) "Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and out-come", Haematologica, 82, 171 — 177.
   PubMed Web of Science ®Google Scholar
• Greer, J.P., York, J.C., Cousar, J.B., Mitchell, R.T., Flexner, J.M., Collins, RD. et al. (1984) "Peripheral T-cell lymphoma: a clinicopathologic study of 42 cases", J. Clin. Oncol., 2, 788–798.
   Web of Science ®Google Scholar
• Shimizu, K., Nagasaka, T., Hara, K., Ohnishi, K., Hirano, M. and Kunii, A. (1989) "Peripheral T-cell lymphoma: clinicopathologic analyses of 25 cases", Jpn. J. Med., 28, 569 — 576.
   Google Scholar
• Thirdborough, S.M., Radcliffe, J.N., Friedmann, P.S. and Stevenson, F.K. (2002) "Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma", Cancer Res., 62, 1757 — 1760.
   Google Scholar
• Meusers, P., Hense, J. and Brittinger, G. (1997) "Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems", Leukemia, 11\(Suppl 2), S60 — S64.
   PubMed Web of Science ®Google Scholar
• Norton, A.J., Matthews, J., Pappa, V., Shamash, J., Love, S., Rohatiner, A.Z., et al. (1995) "Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period", Ann. °flea, 6, 249–256.
   Google Scholar
• Argatoff, L.H., Connors, J.M., Klasa, R.J., Horsman, D.E. and Gascoyne, R.D. (1997) "Mantle cell lymphoma: a clinicopatholo-gic study of 80 cases", Blood, 89, 2067–2078.
   PubMed Web of Science ®Google Scholar
• Zucca, E., Roggero, E., Pinotti, G., Pedrinis, E., Cappella, C., Venco, A., et al. (1995) "Patterns of survival in mantle cell lymphoma", Ann. °flea, 6, 257–262.
   Google Scholar
• Teodorovic, I., Pittaluga, S., Kluin-Nelemans, J.C., Meerwaldt, J.H., Hagenbeek, A., van Glabbeke, M., et al. (1995) "Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group", J. Clin. °ilea, 13, 28 19 — 2826.
   Google Scholar
• Decaudin, D., Bosq, J., Tertian, G., Nedellec, G., Bennaceur, A., Venuat, AM., et al. (1998) "Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas", J. Clin. Oncol., 16, 579 — 583.
   Web of Science ®Google Scholar
• Zinzani, P.L., Magagnoli, M., Moretti, L., Battista, R., Ronconi, F., De Renzo, A., et al. (1999) "Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients", Haematologica, 84, 1002–1006.
   PubMed Web of Science ®Google Scholar
• Foran, J.M., Rohatiner, A.Z., Coiffier, B., Barbui, T., Johnson, S.A., Hiddemann, W., et al. (1999) "Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lympho-plasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma", J. Clin. Oncol., 17, 546— 553.
   Web of Science ®Google Scholar
• Seymour, J.F., Grigg, A.P., Szer, J. and Fox, R.M. (2002) "Cisplatin, fludarabine, and cytarabine: a novel, pharmacologi-cally designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lympho-ma", Cancer, 94, 585–593.
   Google Scholar
• Reiman, T., Graham, K.A., Wong, J., Belch, AR., Coupland, R., Young, J., et al. (2002) "Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study", Leukemia, 16, 1886— 1887.
   PubMed Web of Science ®Google Scholar
• Hideshima, T., Richardson, P., Chauhan, D., Palombella, Vi., Elliott, P.J., Adams, J. et al. (2001) "The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells", Cancer Res., 61, 3071 —3076.
   Google Scholar
• Goy, A.H., East, K., Mesina, 0., Cabanillas, F., Fayed, L., Hagemeister, F., et al. (2003) "Report of a phase II study of proteosome inhibitor bortezomib in patients with relapsed and refractory indolent and aggressive B-cell lymphomas", Proc. Am. Soc. Clin. Oncol., 21, 570 (Abstract 2291).
   Google Scholar
• Pham, L., Tamayo, A., Lo, P., Yoshimura, L. and Ford, R.J. (2001) Anti-tumor activity of the proteosome inhibitor PS-341 in mantle cell lymphoma B-cells", Blood, 98, 465a (Abstract 1945).
   Google Scholar
• Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., et al. (1998) "Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study", Blood, 92, 1927 — 1932.
   Google Scholar
• Foran, J.M., Rohatiner, AZ., Cunningham, D., Popescu, R.A., Solal-Celigny, P., Ghielmini, M., et al. (2000) "European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and pre-viously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma", J. Clin. Oncol., 18, 317— 324.
   Google Scholar
• Foran, J.M., Cunningham, D., Coiffier, B., Solal-Celigny, P., Reyes, F., Ghielmini, M., et al. (2000) "Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response", Ann. °flea, 11\(Suppl 1), 117–121.
   Google Scholar
• Ghielmini, M., Schmitz, S.F., Burki, K., Pichert, G., Betticher, D.C., Stupp, R., et al. (2000) "The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)", Ann. °flea, 11(Suppl 1), 123–126.
   Google Scholar
• Herold, M., Dolken, G., Fiedler, F., Franke, A., Freund, M., Helbig, W., et al. (2003) "Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab", Ann. Hematol., 82, 77–79.
   Web of Science ®Google Scholar
• Hiddemann, W., Dreyling, M. and Unterhalt, M. (2003) "Ritux-imab plus chemotherapy in follicular and mantle cell lymphomas", Semin. °flea, 30, 16–20.
   Google Scholar
• Hiddemann, W., Forstpointer, R., Fiedler, F., Gramatzki, M., Dorken, B., Illiger, H., et al. (2002) "Combined immuno-chemotherapy (R-FCM) is superior to a fludarabine-containing regimen (FCM) alone in recurrent follicular and mantle cell lymphoma; results of a prospective randomized comparison of the German low grade lymphoma study group", Ann. Oncol., 13, 57 (Abstract 186).
   Google Scholar
• Khouri, IF., Romaguera, J., Kantarjian, H., Palmer, J.L., Pugh, W.C., Korbling, M., et al. (1998) "Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma", J. Clin. °flea, 16, 3803 — 3809.
   Google Scholar
• Romaguera, J., Cabanillas, F., Dang, N., Goy, A., Fayad, L., Hagemeister, F.B., et al. (2002) "Mantle cell lymphoma (MCL) — update on results after R-HCVAD without stem cell transplant (SCF)", Ann. °flea, 13, 8 (Abstract 24).
   Google Scholar
• Freedman, AS., Neuberg, D., Gribben, J.G., Mauch, P., Soiffer, R.J., Fisher, D.C., et al. (1998) "High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission", J. Clin. °flea, 16, 13–18.
   Google Scholar
• Mangel, J., Buckstein, R., Imrie, K., Spaner, D., Crump, M., Tompkins, K., et al. (2002) "Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplanta-tion for mantle cell lymphoma", Semin. Oncol., 29, 56–69.
   Google Scholar
• Flinn, I.W., O'Donnell, P.V., Goodrich, A., Vogelsang, G., Abrams, R., Noga, S., et al. (2000) "Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma", Biol. Blood Marrow Transplant, 6, 628–632.
   PubMed Web of Science ®Google Scholar
• Magni, M., Di Nicola, M., Devizzi, L., Matteucci, P., Lombardi, F., Gandola, L., et al. (2000) "Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion", Blood, 96, 864–869.
   Google Scholar
• Gianni, AM., Cortelazzo, S., Magni, M. and Martelli, M. (2002) "Rituximab: enhancing stem cell transplantation in mantle cell lymphoma", Bone Marrow Transplant. 29\(Suppl 1), S10 —13.
   Google Scholar
• Behr, TM., Griesinger, F., Riggert, J., Gratz, S., Behe, M., Kaufmann, CC., et al. (2002) "High-dose myeloablative radio-immunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and auto-logous stem cell support. Results of a pilot study", Cancer, 94, 1363— 1372.
   Google Scholar
• Gopal, AK., Rajendran, J.G., Petersdorf, S.H., Maloney, D.G., Eary, J.F., Wood, B.L., et al. (2002) "High-dose chemo-radio-immunotherapy with autologous stem cell support for relapsed mantle cell lymphoma", Blood, 99, 3158— 3162.
   Google Scholar
• Linch, D.C., Smith, P., Hancock, B.W., Hoskin, P.J., Cunning-ham, D.C., Newland, AC., et al. (2000) "A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma", Ann. Oncol., 11\(Suppl 1), 87–90.
   PubMed Web of Science ®Google Scholar
• Bouabdallah, R., Coso, D., Costello, R., Bardou, Vi., Blaise, D., Xerri, L., et al. (2000) "Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center", Bone Marrow Transplant, 25, 35–40.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans, H.C., Zagonel, V., Anastasopoulou, A., Bron, D., Roozendaal, K.J., Noordijk, E.M., et al. (2001) "Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study", J. Natl. Cancer Inst., 93, 22–30.
   Google Scholar
• Linch, D.C., Yung, L., Smith, P., MacLennan, K.A., Jack, A., Hancock, B.W., et al. (2002) "A randomised trial of CHOP x vs CHOP x 3 BEAM and ASCT in 457 patients with poor prognosis biologically aggressive non-Hodgkin's lymphoma", Ann. Oncol., 20, 28 6–8 (Abstract 85).
   Google Scholar
• Santini, G., Salvagno, L., Leoni, P., Chisesi, T., De Souza, C., Sertoli, MR., et al. (1998) "VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group", J. Clin. Oncol., 16, 2796–2802.
   Web of Science ®Google Scholar
• Santini, G., Olivieri, A., Majolino, I., Congiu, AM., Chisesi, T., Salvagno, L., et al. (2002) "VACOP-B versus VACOP-B + high dose sequential therapy (HDS) for aggressive non-Hodgkin's Lymphoma (NHL)", Ann. Oncol., 20, 75 (Abstract 251).
   Google Scholar
• Gaspard, M.H., Maraninchi, D., Stoppa, AM., Gastaut, J.A., Michel, G., Tubiana, N., et al. (1988) "Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies", Cancer Chemother. Pharmacol., 22, 256 — 262.
   Web of Science ®Google Scholar
• Nademanee, A., Schmidt, G.M., O'Donnell, MR., Snyder, D.S., Parker, PA., Stein, A., et al. (1992) "High-dose chemoradiother-apy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study", Blood, 80, 1130 — 1134.
   Google Scholar
• Santini, G., Coser, P., Congiu, AM., Salvagno, L., De Souza, C., Sertoli, MR., et al. (2000) "VACOP-B, high-dose cyclo-phosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group", Haematologica, 85, 160 — 166.
   Google Scholar
• Stahel, R.A., Jost, L.M., Kroner, T., Dommann-Scherrer, C., Maurer, R., Glanzmann, C., et al. (1999) "A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remission", Br. J. Haematol., 104, 763–769.
   PubMed Web of Science ®Google Scholar
• Stoppa, AM., Bouabdallah, R., Chabannon, C., Novakovitch, G., Vey, N., Camerlo, J., et al. (1997) "Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma", J. Clin. Oncol., 15, 1722— 1729.
   Google Scholar
• Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuczman, M.S., Emmanouilides, C., Joyce, R., et al. (2002) "Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for pa-tients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma", J. Clin. Oncol., 20, 2453–2463.
   Web of Science ®Google Scholar
• Leonard, J.P., Zelenetz, AD., Vose, J.M., Radford, J.A., Wahl, R.L., Rohatiner, A., et al. (2000) "Iodine 1131 tositumomab for patients with low-grade or transformed low-grade NHL: Complete response data", Blood, 96, 782a (Abstract 3148).
   Google Scholar
• Czuczman, M.S., Straus, D.J., Divgi, CR., Graham, M., Garin-Chesa, P., Finn, R., Myers, J., et al. (1993) "Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma", J. Clin. Oncol., 11, 2021 —2029.
   PubMed Web of Science ®Google Scholar
• Linden, 0., Tennvall, J., Hindorf, C., Cavallin-Stahl, E., Lindner, K.J., Ohlsson, T., et al. (2002) "131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates", Acta. Oncol., 41, 297–303.
   PubMed Web of Science ®Google Scholar
• Griffiths, G.L., Govindan, S.V., Sharkey, R.M., Fisher, D.R. and Goldenberg, D.M. (2003) "90Y-DOTA-hLL2: an agent for radio-immunotherapy of non-Hodgkin's lymphoma", J. Nucl. Med., 44, 77–84.
   Web of Science ®Google Scholar
• Yordanov, AT., Garmestani, K., Zhang, M., Zhang, Z., Yao, Z., Phillips, K.E., et al. (2001) "Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac", Nucl. Med. Biol., 28, 845–856.
   Google Scholar
• DeNardo, G.L., DeNardo, S.J., Shen, S., DeNardo, D.A., Mirick, G.R., Macey, D.J., et al. (1999) "Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia", J. Nucl. Med., 40, 1317 — 1326.
   Web of Science ®Google Scholar
• O'Donnell, R.T., DeNardo, G.L., Kukis, D.L., Lamborn, KR., Shen, S., Yuan, A., et al. (1999) "A clinical trial of radio-immunotherapy with 67Cu-21T-BAT-Lym-1 for non-Hodgkin's lymphoma", J. Nucl. Med., 40, 2014 — 2020.
   Google Scholar
• Foss, F.M., Raubitscheck, A., Mulshine, J.L., Fleisher, TA., Reynolds, J.C., Paik, C.H., et al. (1998) "Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma", Clin. Cancer Res., 4, 2691— 2700.
   Web of Science ®Google Scholar
• Chakrabarti, MC., Paik, C.H. and Carrasquillo, J.A. (1999) "Preparation and in vitro studies of [125I]IUDR-T101 antibody conjugate", Cancer Biother. Radiopharm., 14, 91–98.
   Google Scholar
• Gordon, L.I., Witzig, T.E., Emmanouilides, C., Raubitschek, A., Spies, S., Wiseman, G., et al. (2002) "90Y ibritumomab (Zevalin) in aggressive non-Hodgkin's lymphoma: analysis of response and toxicity", Proc. Am. Soc. Clin. Oncol., 21, 266a (Abstract 1061).
   Google Scholar
• Bartlett, N.L., Witzig, T.E., Beck, TM., Fehrenbacher, L., Kornmehl, E., Levy, R., et al. (2002) "90-Y-ibritumomab tiuxitan (Zevalin) radioimmunotherapy for transformed B-CLL non-Hodgkin's lymphoma", Proc. Am. Soc. Clin. Oncol., 21, 14a (Abstract 51).
   Google Scholar
• Davies, A.J., Radford, J.A., Britton, K., Howell, S., Deakin, D.P., Micallef, IN., et al. (2001) "A phase II study of Bexxar (tositumomab and tositumomab) for patients at 1st or 2nd recurrence of B-cell non Hodgkin's lymphoma", Proc. Am. Soc. Clin. Oncol., 20, 286a 1–131(Abstract 1142).
   Google Scholar
• Press, 0.W., Eary, J.F., Appelbaum, FR., Martin, P.J., Badger, CC., Nelp, W.B., et al. (1993) "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support", N. Engl. J. Med., 329, 1219–1224.
   PubMed Web of Science ®Google Scholar
• Press, 0.W., Eary, J.F., Appelbaum, FR., Martin, P.J., Nelp, W.B., Glenn, S., et al. (1995) "Phase II trial of 131-1-BI (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas", Lancet, 346, 336— 340.
   Google Scholar